CHTP and ALKS halt further trials following disappointing trial data + OMER news

May 31, 2012 No Comments by

Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it failed to meet its primary endpoint in its Phase 2 trial of CH-4051 in patients with rheumatoid arthritis (RA). As a result it plans to discontinue development of CH-4051.

Alkermes plc (NASDAQ: ALKS) said that it did not meet its “pre-specified criteria for advancing into Phase 3 clinical trials” following data from its Phase 2b trial of ALKS 37 in the treatment of opioid-induced constipation. The company said it has no further plans to advance ALKS 37.

Omeros Corporation (NASDAQ: OMER) today maintained previous guidance that it plans to announce data from its second Phase 3 OMS302 trial, in patients undergoing intraocular lens replacement (ILR) surgery, in 2H 2012 and, assuming positive results, to file both an NDA and MAA in the first part of 2013.

Daily News

About the author

Currently residing in New Zealand and employed in the education industry, Mr. A. Burden holds a M.Com in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.
No Responses to “CHTP and ALKS halt further trials following disappointing trial data + OMER news”

Leave a Reply